



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC Handels GmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic)



PRODUCT INFORMATION

Common Name	CX-191, Unconjugated mAb
Conjugate	Unconjugated
Synonyms	ALCAM;MEMD
Applications	Flow Cyt
Recommended Dilutions	Flow Cyt 1:100
Formulation & Reconstitution	Lyophilized from sterile PBS, pH 7.4. Normally 5 % - 8% trehalose is added as protectants before lyophilization. Please see Certificate of Analysis for specific instructions of reconstitution.
Host Species	Humanized
IgG type	IgG1
Reactivity	Human
Target	CD166
Uniprot ID	Q13740
Description	Anti-CD166(praluzatamab biosimilar) mAb
Delivery	In Stock
Storage & Shipping	Store at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing). Lyophilized proteins are shipped at ambient temperature.
Background	Research grade biosimilar. Not for use in therapeutic or diagnostic procedures for humans or animals. Our unconjugated biosimilar monoclonal antibodies (mAbs) are based on the sequences outlined in relevant patents or scientific publications. These antibodies are in their native, unconjugated form, meaning they do not contain any payload or therapeutic agent attached. They are designed for use in research and development, and their performance has been tested as standalone molecules through comprehensive QC tests.
Usage	Research use only
DIMA Disclaimer	All DIMA recombinant antibodies are genuinely generated by DIMA Biotech. They are all under patent application. Any protein sequencing or reverse engineering attempt is prohibited. We are actively scrutinizing all patent application to ensure no IP infringement.






Figure 1. CD166 protein is highly expressed on the surface of Expi293 cell membrane. Flow cytometry analysis with 15 μ g/mL Anti-CD166(praluzatamab biosimilar) mAb (BME100172) on Expi293 cells transfected with Human CD166 (Blue histogram) or Expi293 transfected with irrelevant protein (Red histogram), and Isotype antibody on Expi293 transfected with irrelevant protein (Orange histogram).




Figure 2. Flow cytometry analysis of antigen binding of anti-human CD166 mAb(BME100172).

(A) BME100172 does not bind to K562 cells that do not express CD166.

(B) A clear peak shift of BME100172 was seen compared to the control when incubated with CD166-expressing Hela cells, indicating strong binding of BME100172 to CD166. Antibodies were incubated at 5 μ g/mL.






Figure 3. Flow cytometry analysis of antigen binding of anti-human CD166 mAb(BME100172).
(A) BME100172 does not bind to K562 cells that do not express CD166.
(B) A clear peak shift of BME100172 was seen compared to the control when incubated with CD166-expressing Huh7 cells, indicating strong binding of BME100172 to CD166. Antibodies were incubated at 5 µg/mL.

